Table 4 Proportion of participants positive for SARS-CoV-2 (N = 74) with a 95% confidence interval (95% CI) in six cross-sectional population surveys by reported symptom and recall period in Sweden in 2020
From: Point prevalence of SARS-CoV-2 infection in Sweden at six time points during 2020
Symptom | Recall period | |||||
|---|---|---|---|---|---|---|
2 weeks before self-sampling (n = 72) | 24 h before self-sampling (n = 72) | 1 week after self-sampling (n = 74) | ||||
% | (95% CI) | % | (95% CI) | % | (95% CI) | |
Chills | 13.9 | (6.9–24.1) | 43.1 | (31.4–55.3) | 18.1 | (10.0–28.9) |
Cough | 50.0 | (38.0–62.0) | 62.5 | (50.3–73.6) | 45.8 | (34.2–58.0) |
Diarrhoea | 18.1 | (10.0–28.9) | 25.0 | (15.5–36.6) | 16.7 | (8.2–27.0) |
Ear pain | 6.9 | (2.3–15.5) | 12.5 | (5.9–22.4) | 8.3 | (3.1–17.3) |
Extreme fatigue, exhaustion | 41.7 | (30.2–53.9) | 63.9 | (51.7–74..9) | 52.8 | (40.7–64.7) |
Eye discharge | 15.3 | (7.9–25.7) | 16.7 | (8.9–27.3) | 16.7 | (8.9–27.0) |
Fever | 19.4 | (11.1–30.5) | 54.2 | (42.0–66.0) | 20.8 | (12.2–32.0) |
Headache | 48.6 | (36.7–60.7) | 77.8 | (66.4–86.7) | 52.8 | (40.7–64.7) |
Joint pain | 20.8 | (12.2–32.0) | 37.5 | (26.4–49.7) | 25.0 | (15.5–36.6) |
Loss of smell | 27.8 | (17.9–39.6) | 37.5 | (26.4–49.7) | 45.8 | (34.2–58.0) |
Loss of taste | 34.7 | (23.9–46.9) | 37.5 | (26.4–49.7) | 43.1 | (31.4–55.3) |
Myalgia | 25.0 | (15.5–36.6) | 40.3 | (28.9–52.5) | 30.6 | (20.2–42.5) |
Nausea | 18.1 | (10.0–28.9) | 31.9 | (21.4–44.0) | 18.1 | (10.0–28.9) |
Nosebleeds | 5.6 | (1.5–13.6) | 13.9 | (6.9–24.1) | 8.3 | (3.2–17.3) |
Runny nose | 58.3 | (46.1–69.9) | 65.3 | (53.1–76.1) | 50.0 | (38.0–62.0) |
Shortness of breath,difficulty breathing | 11.1 | (4.9–20.7) | 20.8 | (12.2–32.0) | 31.9 | (21.4–44.0) |
Skin rashes such as hives, dots, pustules or blisters | 6.9 | (2.3–15.5) | 6.9 | (2.39–15.5) | 5.6 | (1.5–13.6) |
Sore throat | 23.6 | (14.4–35.1) | 48.6 | (36.7–60.7) | 31.9 | (21.4–44.0) |
Stomach ache | 18.1 | (10.0–28.9) | 31.9 | (21.4–44.0) | 19.4 | (11.1–30.5) |
Vomiting | 2.8 | (0.3–9.7) | 4.2 | (0.9–11.7) | 4.2 | (0.9–11.7) |
No symptoms | 4.2 | (0.9–11.7) | 2.8 | (0.3–9.7) | 5.6 | (1.5–13.6) |